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BACKGROUND: We examined the ability of the apolipoprotein AI mimetic peptide L-4F to improve the metabolic state
of female and male ob mice and the mechanisms involved.
METHODS: Female and male lean and obese (ob) mice were administered L-4F or vehicle for 6 weeks. Body weight was
measured weekly. Fat distribution, serum cytokines and markers of cardiovascular dysfunction were determined at the
end of treatment.
RESULTS: L-4F signiﬁcantly decreased serum interleukin (IL)-6, tumor necrosis factor-a and IL-1b. L-4F improved vascular
function, and increased serum adiponectin levels and insulin sensitivity compared with untreated mice. In addition, L-4F
treatment increased heme oxygenase (HO)-1, pAKT and pAMPK levels in kidneys of ob animals. pAKT and pAMPK levels were
signiﬁcantly reduced in the presence of an HO inhibitor. Interestingly, L4F did not alter body weight in female mice,
but caused a signiﬁcant reduction in males.
CONCLUSIONS: L-4F treatments reduced cardiovascular risk factors and improved insulin sensitivity in female ob mice
independent of body fat changes. Reduced inﬂammatory cytokine levels accompanied by increased HO activity, serum
adiponectin and improved insulin sensitivity suggest that L-4F may promote the conversion of visceral fat to a healthier
phenotype. Therefore, L-4F appears to be a promising therapeutic strategy for treating both cardiovascular risk factors
and insulin resistance in obese patients of either gender.
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INTRODUCTION
Obesity affects over 72 million adults in the United States with a
disproportionate prevalence in women.
1,2 Moderate to severe
obesity is associated with increased risk for cardiovascular
complications and insulin resistance in humans
3,4 and animals.
5
In particular, intra-abdominal fat correlates with insulin resistance
and is an important determinant of cardiovascular risk.
6 Although
men have received much attention for exhibiting such ‘android’
obesity, excess visceral fat deposition is present in 41% of women
in Western countries (www.dh.gov.uk).
Visceral obesity creates a state of low-grade inﬂammation
characterized by increased pro-inﬂammatory cytokine levels
7- -9
that contributes to insulin resistance
10 and oxidative stress that
impairs vascular and cardiac function.
5 Indeed, mice lacking tumor
necrosis factor (TNF)-a have signiﬁcantly improved insulin
sensitivity and glucose homeostasis in response to diet-induced
obesity.
11- -13 In addition, ob mice overexpressing adiponectin
have reduced inﬂammation and improved insulin sensitivity,
accompanied by an increase in adipocyte number and smaller
adipocyte size.
14 These data suggest that promoting the
expansion of adipocyte number may prevent or stave off the
negative inﬂammatory effects of larger adipocytes. The increase in
inﬂammatory cytokine production observed with obesity may
result from an increase in reactive oxygen species.
5,15 It has been
reported that reactive oxygen species produced by adipocytes
increases the expression of MCP-1, a chemoattractant for
macrophages, a key producer of such cytokines.
5 This increase
in reactive oxygen species contributes to progressive deterioration
in vascular function.
5
Abnormal high-density lipoprotein cholesterol (HDL-c) metabo-
lism may also contribute to the increased cardiovascular disease
risk caused by diabetes and obesity. The HDL-c particle distribu-
tion is abnormal in both types 1 and 2 diabetes, with decreases
in the relative fraction of the large HDL-c particles believed to be
cardioprotective.
16 Apolipoprotein A-I (apoA-1) is the major
protein component of HDL-c in plasma. The level of apoA-I is
more closely correlated with the reduced risk of atherosclerosis
than any other marker of HDL-c.
17 ApoA-I prevents the oxidation
and aggregation of pro-atherogenic low-density lipoprotein
cholesterol (LDL-c) particles within the arterial wall and stimulates
the mobilization of cholesterol from the same source.
18 Infusion of
apoA-I halts the progression of atherosclerosis and promotes its
regression, reverses endothelial dysfunction, and induces lipid and
macrophage efﬂux from established lesions in animals.
19- -21
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www.nature.com/nutdMuch effort has gone into designing peptide analogs of apoA-I
that can promote the formation of HDL-c-like particles with
improved potency or efﬁcacy in vivo. L-4F, an apoA-1 mimetic
peptide, improves insulin resistance in male ob mice, reduces
inﬂammatory cytokines, reestablishes nitric oxide (NO)/superoxide
ratios and reduces consequent cardiovascular risk.
22,23 Its en-
antiomer, D-4F, reduces atherosclerotic lesions,
24 causes HDL-c to
become anti-inﬂammatory, stimulates HDL-c-mediated cholesterol
efﬂux and increases reverse cholesterol transport from macro-
phages.
5,24 In a phase 1 human trial, a single oral dose of D-4F
improved HDL-c anti-inﬂammatory function.
25 D-4F has also been
shown to reduce the size of white adipose tissue stores
(but not body weight) in male mice fed with a high-fat diet,
26
and to decrease visceral fat in male ob mice.
22,23 L-4F is currently
in clinical trials and has been hailed as being especially promising
as a potential treatment for obesity and the metabolic
syndrome.
27 However, the actions of L-4F in female ob mice in
addition to the efﬁcacy of L-4F in improving markers of vascular
function in obese mice remain to be examined.
Heme oxygenase 1 (HO-1) induction is known to suppress ROS
production and promote increases in insulin sensitivity.
5 In this
study, we evaluated the mechanism by which L-4F affected HO-1
and subsequently, visceral and subcutaneous fat distribution in
female and male ob mice. We then examined whether reduced
visceral obesity is essential for the improved metabolic proﬁle
seen in L-4F-treated animals. Male and female ob mice treated
with L-4F had signiﬁcant improvements in insulin sensitivity and
reduced inﬂammatory cytokine levels. However, we show for the
ﬁrst time that administration of L-4F in ob female mice decreases
inﬂammatory cytokines and improves insulin responsiveness
independent of changes in body weight. Furthermore, L-4F was
effective in restoring HO-1 dependent increases in NO levels in
female ob mice, indicating improved vascular function, and
restored superoxide production and systolic blood pressure in
male ob mice. Last, L-4F treatment resulted in a marked increase
in heme oxygenase (HO) activity in both male and female ob mice.
Therefore, L-4F has the potential to have a crucial therapeutic role
in improving metabolic syndrome parameters and indices of
vascular function-associated poor cardiovascular health.
MATERIALS AND METHODS
Animal care and L-4F administration
Male and female ob mice (B6v-Lep ob/J) were purchased from Harlan
(Chicago, IL, USA) at the age of 6 weeks. Lean mice (age-matched B6.V,
lean, Harlan) were used as control. Sex-matched lean and ob mice were fed
a normal laboratory animal diet (Research diets, New Brunswick, NJ, USA)
and had free access to water. Body weight of ob and lean mice were
34±5g and 26±3g, respectively, and glucose levels were 229±21mg
dl
 1 and 154±9mgdl
 1, respectively, at the start of the experiments.
At 7 weeks of age, L-4F (2mgkg
 1 per day) or vehicle (ABCT:
ammonium bicarbonate buffer at pH 7.4 containing 0.01% Tween-20),
was administered intraperitoneally daily for 6 weeks to male and female ob
and lean control mice. There were 10 groups of animals: (A) male lean, (B)
male lean-L-4F, (C) male ob, (D) male ob-L-4F, (E) male ob-L-4FþSnMP
(stannous mesoprophryin was given intraperitoneally 2mg per 100g body
weight three times per week), (F) female lean, (G) female lean-L-4F, (H)
female ob, (I) female ob-L-4F and (J) female ob-L-4FþSnMP. Systolic blood
pressure was determined weekly by the tail-cuff method as previously
described.
28 The Animal Care and Use Committee of New York Medical
College approved all experiments.
Effect on body weight, appearance and fat content
At the time of killing, the body weight of all mice was measured.
The subcutaneous and visceral fat visible in the abdomen, mesenteric fat,
fat around the liver, kidney, spleen, heart, ovaries and testes were
dissected free, pooled for each mouse and weighed. Subcutaneous and
visceral fat were weighed separately.
Glucose levels and insulin tolerance tests
Mouse blood glucose was determined by testing 5ml of tail-vein blood
using an Accu-Chek (Roche, Indianapolis, IN, USA) active blood glucose-
monitoring system. After a 12-h fast, mice were injected intraperitoneally
with insulin (2.0 unitskg
 1). Blood samples were taken at 0 (basal), 30, 60,
75 and 90min, and used to measure glucose levels.
LDL/VLDL and cytokine measurements
Serum LDL/VLDL (very low-density lipoprotein) cholesterol levels were
measured in serum collected at the time of killing (24-h post previous
injection) using LDL/VLDL Quantiﬁcation Kits (Biovision, Mountainview, CA,
USA). Adiponectin (high molecular weight), TNF-a, interleukin (IL)-1b and
IL-6 were determined in mouse serum using an enzyme-linked immuno-
sorbent assay assay (Pierce Biotechnology, Woburn, MA, USA). The assays
were performed according to the manufacturer’s guidelines.
Measurement of cardiac superoxide (O2
 ) levels
The hearts were placed in plastic scintillation minivials, containing
5mmoll
 1 lucigenin for the detection of O2
 , in a ﬁnal volume of 1ml of
air-equilibrated Krebs solution buffered with 10mmolM
 1 HEPES- -NaOH
(pH 7.4) as previously described.
29 Lucigenin chemiluminescence was
measured in a liquid scintillation counter (LS6000IC, Beckman Instruments,
San Diego, CA, USA).
Determination of HO activity and NO levels
Aortic HO activity was assayed as described previously.
30 Bilirubin, the
end product of heme degradation, was extracted from chloroform,
and its concentration was determined using the difference in absorbance
between l460 and l530nm with an absorption coefﬁcient of
40mM
 1cm
 1 (dual UV/VIS beam spectrophotometer lambda 25;
PerkinElmer Life and Analytical Sciences, Wellesley, MA, USA). Under
these conditions, HO activity was linear with protein concentration,
time-dependent and substrate-dependent.
31
For NO levels in whole kidney and aorta homogenate samples, 0.3mg of
protein were evaluated by measuring total nitrite and nitrate content
in culture medium using the NO quantiﬁcation kit and following the
manufacturer’s instructions (Active Motif, Carlsbad, CA, USA).
Western blot analysis of the kidney and aorta for HO-1, pAMPK
and pAkt expression
At the time of killing, aorta and kidney were harvested, drained of blood and
ﬂash frozen in liquid nitrogen. Frozen aorta and kidney segments were
pulverized and placed in a homogenization buffer as previously described.
32
Homogenates (20- -50mg of protein) were examined by protein immunoblot.
HO-1, HO-2,
22 AMPK, pAMK, AKT and pAkt (Cell Signaling, Danvers, MA, USA)
levels were determined as previously described.
22
Statistical analyses
Statistical signiﬁcance was determined by the Fisher method of analysis of
multiple comparisons (Po0.05). For comparisons among treatment
groups, the null hypothesis was tested by a two-factor analysis of variance
for multiple groups or unpaired t-test for two groups. Data are presented
as mean±s.e.
RESULTS
Effects of L-4F on male and female body fat
L-4F treatment daily for 6 weeks prevented weight gain in ob male
mice in accordance with previous ﬁndings (Figure 1a). Unexpect-
edly, ob female mice that received L-4F continued to gain weight
at a rate similar to untreated ob mice (Figure 1a). Food intake in
the male and female ob control and treated groups were
comparable (ob male¼3.66±0.35g per day; ob maleþ
L-4F¼3.6±0.2g per day; ob female¼3.5±0.26g per day;
and ob femaleþL-4F¼3.55±0.1g per day). At the end of the
6-week treatment period, L-4F slightly decreased the ratio of
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females (Figure 1b). However, the ratio of visceral fat to whole
body weight was decreased only in L-4F-treated males (Figure 1c).
Female mice treated with L-4F showed a small but signiﬁcant
increase in the visceral fat to body weight ratio compared with
controls (Figure 1c). The changes we measured in the fat to body
weight ratio are consistent with the changes that were measured
in body weight, which suggests that L-4F treatment may indeed
cause sexually dimorphic responses.
Effects of L-4F on glucose levels and insulin tolerance tests
Chronic L-4F treatment reduced high fasting plasma glucose levels
in ob males and females (Figure 2a). In addition, insulin
administration to the L-4F-treated ob female mice resulted in a
signiﬁcant suppression of blood glucose levels but not in
ob females receiving vehicle alone (Figure 2b). Last, the area
under the curve determined for the data presented in Figure 2b
was higher in vehicle compared with L-4F-treated ob females
(Figure 2c). These results suggest that L-4F restores insulin
sensitivity in female ob mice independent of changes in body
weight (Figure 1a).
Effects of L-4F on adiponectin and cytokine levels
It has been shown that overexpression of adiponectin in the
ob mouse model leads to expansion of adipose tissue.
33 We have
previously shown that L-4F increases adiponectin levels in male
mice.
22 We therefore examined whether male and female mice
show a difference in adiponectin responses to L-4F. L-4F produced
a signiﬁcant increase in plasma adiponectin levels in both ob
female and male animals (Figure 3a). However, adiponectin levels
in ob female mice were increased compared with ob male mice
treated with L-4F, suggesting that adipose tissue maintenance and
expansion in ob female mice may result from increased
adiponectin levels.
14
We also examined circulating levels of cytokines that are
typically associated with obesity-mediated insulin resistance and
vascular dysfunction. Female ob animals initially exhibited
increased plasma IL-6 levels when compared with age-matched
ob male mice (Figure 3b). L-4F produced a decrease in plasma IL-6
levels in both ob female and male mice when compared with
untreated controls. Similar results were observed for plasma TNF-a
and IL-1b levels (Figures 3c and d). Thus, although visceral fat is
not lost in the female ob mice treated with L-4F, the inﬂammatory
cytokine state is markedly improved, suggesting that the adipose
tissue is healthier.
14
Effects of L-4F on blood pressure and vascular function
In addition to metabolic defects, ob mice have altered cardiac
function, which is a common consequence of obesity. Figure 4a
shows that ob male mice are hypertensive compared with lean
controls. L-4F treatment was highly successful in restoring systolic
blood pressure to levels matching lean controls (Figure 4a).
Additionally, ob male mice had signiﬁcantly elevated cardiac
superoxide levels, an indicator of oxidative stress (Figure 4b).
Following L-4F treatment, superoxide production was normalized
(Figure 4b). Aortic NO contributes to endothelial function and
protects against hypertension. NO release from the aorta of
ob female mice was reduced compared with lean female mice
(Figure 4c). This decrease in NO was ameliorated by L-4F
treatment (Figure 4c). These results indicate that L-4F may have
a role in vascular protection in obese mice.
Mice homozygous for the obese spontaneous mutation (ob
mice) have elevated circulating free fatty acids, raised triglycer-
ides, an increase in both low-density lipoprotein (LDL) and high-
density lipoprotein (HDL) cholesterol and marked hepatic
steatosis.
34- -36 In these mice, L-4F was effective in reducing the
LDL/VLDL cholesterol ratio in both ob males and females
(Figure 4e).
Effects of L-4F on HO-1 expression and HO activity
Obesity has been linked with increases in adipocyte oxidative
stress, while HO-1 is strongly induced by oxidant stress and helps
Figure 1. Effect of L-4F on body composition in ob mice after 6 weeks of L-4F treatment (2mgkg
 1 per day) or control (a) Effect of L-4F
treatment on body weight. ob male and female mice, respectively, were treated and weight determined (average of two independent
experiments), n¼10 for untreated and treated ob groups. Results are means±s.e. Levels of signiﬁcance: *Po0.05 vs ob maleþvehicle.
(b) Effect of L-4F on subcutaneous fat to total body weight ratio. Levels of signiﬁcance: *Po0.01 vs ob male and ***Po0.05 vs ob female.
(c) Effect of L-4F on visceral fat to total body weight ratio. Levels of signiﬁcance: *Po 0.05 vs ob male and
#Po0.05 vs ob female.
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5 Given
that we have previously shown that administration of an HO-1
inducer increases serum adiponectin levels,
29 we wanted to
examine the possibility that L-4F increases adiponectin levels by
raising HO-1 levels. Thus, we examined HO-1 levels in the kidneys
and aortas of ob and lean mice. As in males, HO-1 in both the
aortas (data not shown) and kidneys of ob females differed
signiﬁcantly from lean animals (Figures 5a and b). In addition, HO-
1 levels were signiﬁcantly lower in ob females compared with ob
males (Figure 5b). We next compared the effect of L-4F on male
and female HO-1 protein expression in renal and vascular tissue
samples. L-4F increased HO-1 expression in both ob male and
female animals (Figure 5c). In contrast to the effects on HO-1,
HO-2 levels in renal and vascular tissue samples were unaffected
Figure 2. (a-- c) Fasting glucose and insulin tolerance test. (a) Effect of L-4F treatment on glucose levels in ob male and female mice. The results
are expressed as means±s.e.m., n¼4. Levels of signiﬁcance: *Po0.01 vs ob male and
#Po0.05 vs ob female. (b) Intraperitoneal insulin
tolerance test (IPGTT). The results are expressed as means±s.e.m., n¼4. Levels of signiﬁcance: *Po0.01 and ***Po0.001 vs ob female control.
(c) Area under the curve for IPGTT. The results are expressed as means±s.e.m., n¼4. Levels of signiﬁcance: **Po0.005 vs ob female control.
Figure 3. (a-- d) Effect of L-4F on serum cytokines. L-4F was administered daily for 6 weeks and serum samples were obtained immediately
before killing. (a) Effect of L-4F on serum adiponectin levels in ob male and female mice. The results are expressed as means±s.e., n¼8--10.
Levels of signiﬁcance: *Po0.001 vs ob male,
#Po0.05 vs ob male and
**Po0.05 vs ob female. (b) Effect of L-4F on serum IL-6 levels in ob male
and female mice. Levels of signiﬁcance: *Po0.01 vs ob male,
#Po0.05 vs ob male and
**Po0.05 vs ob female. (c) Effect of L-4F on serum TNF-a
levels in ob mice. Levels of signiﬁcance: *Po0.01 vs ob male and
#Po0.05 vs ob female. (d) Effect of L-4F on IL-1b serum levels in ob female
mice. Levels of signiﬁcance: *Po0.01 vs ob male and
#Po0.05 vs ob female.
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(data not shown). L-4F increased HO activity in the aortic tissue
samples of both ob male and female mice (Figure 5d). The
increase in HO activity was inhibited by SnMP, an inhibitor of HO
activity (Figure 5d). These results indicate that L-4F is an inducer of
HO activity. Thus, the improvements in inﬂammatory cytokines
and indices of cardiovascular function following L-4F treatment
are likely mediated by L-4F-induced increases in HO activity.
To examine the contribution of vascular and renal AKT and
AMPK pathways to the increase in HO-1 expression, we assessed
vascular and renal expression of phosphorylated AMPK and AKT in
L-4F-treated ob males and ob females. As seen in Figure 6, L-4F
signiﬁcantly increased basal renal AKT and AMPK phosphorylation
in both ob males and females. Similar results were obtained with
aortic tissue (data not shown). The addition of SnMP, a potent
inhibitor of HO activity, to L-4F-treated animals reversed this effect
in both ob males and females (Figures 6a--d). These results
suggest that L-4F stimulation of AMPK and AKT pathways is
involved in its ability to increase HO-1 expression and increase
HO activity.
DISCUSSION
The metabolic syndrome is typically characterized by chronic, low-
grade inﬂammation, excessive visceral fat, insulin resistance,
abnormal cholesterol levels and increased blood pressure.
The present study clearly shows for the ﬁrst time that adminis-
tration of the apoA-I mimetic L-4F ameliorates effects associated
with the metabolic syndrome in female ob mice. Intriguingly, the
positive effects of L-4F treatment on metabolic and vascular
function in ob female mice were independent of changes in body
weight. In fact, the visceral fat to body weight ratio increased in
female ob mice treated with L-4F. We report that administration of
L-4F to both ob female and male mice restored insulin sensitivity,
increased serum adiponectin, decreased the LDL/VLDL cholesterol
ratio and decreased serum pro-inﬂammatory cytokines (TNF-a,
IL-6 and IL-1b). Moreover, in ob male mice, L-4F improved systolic
blood pressure and reduced cardiac superoxide production. In
female obese mice, L4F caused an increase in HO-1-mediated NO
levels. These novel ﬁndings suggest that L-4F has the potential to
be a key therapeutic agent in the treatment of both vascular
diseases and insulin resistance in obese patients.
We have previously shown that L-4F administration reduces fat
mass in male ob mice.
22,23 Recent studies suggest that this effect is
mediated by enhanced energy expenditure resulting from
upregulation of UCP1 expression in brown fat.
26 In contrast,
females treated with L-4F did not exhibit a decrease in visceral
body fat over the time course measured (Figure 1c). These results
are in line with the sexual dimorphism frequently observed in
males and females in response to energetic challenges. Instead of
primarily modulating food intake, females defend and build
adipose stores by maintaining low rates of energy expenditure.
37
Indeed, when overfed with a palatable high-fat diet, female
rats gain more body weight than males because of a greater
conservation of energy expenditure with lower activation of
thermogenesis in brown adipose tissue.
38,39
Several factors may contribute to the observed differences
in effect on body fat stores. Kim et al.
14 demonstrated that
overexpression of adiponectin in the ob mouse leads to increased
adipocyte number. Importantly, the adipose expansion in ob mice
overexpressing adiponectin is associated with increases in insulin
sensitivity.
14 More recently, overexpression of adiponectin was
shown to promote a more metabolically ﬂexible adipose tissue
and prevented hepatic lipid accumulation in mice fed with a high-
fat diet.
33 The roughly 1.5-fold elevation of adiponectin seen in
L-4F-treated female ob mice above that seen in males could
therefore promote adipose tissue expansion in ob female mice.
Adipose tissue expansion in the L-4F-treated ob females is
currently being investigated and could explain the increased
visceral fat to body weight ratio despite increased insulin
sensitivity and reduced serum TNF-a, IL-6 and IL-1b in the present
study. This would suggest that L-4F treatment converts the
visceral fat in female ob mice to a healthier phenotype, which may
prevent ectopic lipid accumulation in the liver and skeletal muscle.
In addition, gender differences in HO-1 and sex hormone levels
may favor female adiposity, as estradiol and HO-1 induction lead
to an increase in proliferation of pre-adipocytes.
40,41 It is possible
that female mice require a lengthier L-4F treatment period before
decreases in weight gain are observed. Nevertheless, the retention
of fat mass in the female animals did not impair the ability of L-4F
Figure 4. Effect of L-4F on blood pressure and vascular function. (a) Effect of L-4F on systolic blood pressure. Levels of signiﬁcance: **Po0.01
vs ob vehicle and
#Po0.05 vs ob vehicle. (b) Cardiac superoxide production. Levels of signiﬁcance: *Po0.05 vs ob vehicle and
#Po0.05 vs ob
vehicle. (c) Effects of L-4F on NO levels. Levels of signiﬁcance: *Po0.05 vs ob female and
#Po0.05 vs ob female. (d) Effect of L-4F treatment on
LDL/VLDL levels. Levels of signiﬁcance: *Po0.01 vs ob male and
#Po0.01 vs ob female.
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state of obese females.
HDL-c and apoA-1 have potent anti-inﬂammatory proper-
ties.
42,43 During atherogenesis, cholesterol accumulation in
macrophage foam cells induces inﬂammatory responses, apopto-
sis and other adverse effects.
44 One of the major functions of
HDL-c is to transport cholesterol from these foam cells to the liver
for elimination in the bile.
45 Cells are able to export excess
cholesterol to apoA-1 by virtue of specialized cell membrane
transporters, such as ABCA1, that belong to a superfamily of
ATP-binding cassette transporters (ABCs).
46 Mice lacking ABCA1 in
all tissues or speciﬁcally in macrophages have a heightened
response to treatment with the inﬂammatory stimulus lipopoly-
saccaride,
47 including increased inﬂammatory cytokines in the
circulation, implying that macrophage ABCA1 has an anti-
inﬂammatory function. 4F peptides can mimic apoA-I in removing
cholesterol and phospholipids by the ABCA1 pathway.
48- -51 We are
currently perusing more in-depth studies to uncover the direct
role of the ABCA1 pathway in the effects of apoA-1 mimetic
treatment. In addition to this mechanism, L-4F may reduce
inﬂammation by inhibiting cellular expression of VCAM-1 and
ICAM-1 on coronary endothelial cells, reducing CD11b expression
on circulating monocytes and/or reducing CD11b-dependent
adhesion of leukocytes to ﬁbrinogen.
52
HO-1 is a stress response protein whose induction is associated
with protection against oxidative stress with a concomitant
increase in adiponectin. The current studies indicate that L-4F
treatment decreases oxidative stress in female mice as previously
seen in males.
5,22,23,32 Indeed, HO-1 was dramatically induced in
male mice to levels nearly twofold above those seen in lean
animals, and female increases were even larger. These effects may
underlie many of the beneﬁcial actions of L-4F. For example,
treatment of obese mice with an NADPH oxidase inhibitor
reduced reactive oxygen species production in adipose tissue,
attenuated the dysregulation of adipocytokines, and improved
diabetes, hyperlipidemia and hepatic steatosis.
53 It has been
shown that induction of HO-1 serves as an intrinsic protective
factor against atherosclerotic lesion formation, possibly inhibiting
lipid peroxidation and inﬂuencing the NO pathway.
5 Indeed, ob
female mice exhibited decreased NO levels and elevated LDL/
VLDL cholesterol ratio compared with lean female mice.
Additionally, ob male mice had elevated superoxide production.
These ﬁndings are in line with previous data inducting that
oxidative stress decreases the messenger RNA and protein
expression of ABCA1 and cholesterol efﬂux.
54,55 L-4F administra-
tion, however, improved NO levels while decreasing the LDL/VLDL
cholesterol ratio in ob female mice, and reduced superoxide
production in ob male mice. Increases in HO-1 expression and HO
Figure 5. (a-- d) Effects of L-4F on levels of HO-1 and HO activity. Kidney samples were subjected to western blotting for the determination of
HO-1 protein expression and densitometry analysis of HO-1/actin ratio. (a, b) Expression of HO-1 in the kidney of lean and ob male and female
mice. Results are means±s.e., n¼4. Levels of signiﬁcance: *Po0.05 vs ob male. (c) Effect of L-4F on HO-1 expression in the kidneys of ob
female and male mice. Results are means±s.e., n¼4. Levels of signiﬁcance: *Po0.05 vs ob male, **Po0.01 vs ob male and ***Po0.01 vs ob
female. (d) Effect of L-4F and SnMP on HO activity in the aortas of ob male and female mice. Results are means±s.e., n¼4. Levels of
signiﬁcance: *Po0.001 vs ob male, **Po0.001 vs ob maleþL-4F, ***Po0.001 vs ob female and
#Po0.01 vs ob femaleþL-4F.
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production in adipose tissue.
22 Thus, HO-1 actions may also
account for the reduction in plasma concentration of TNF-a, IL-6
and IL-1b in L-4F-treated mice.
L-4F-treated females also showed a remarkable improvement in
parameters of glucose regulation. There is mounting evidence that
removal of excess cholesterol from pancreatic beta cells via the
ABCA1 has a role in protecting beta cell function and preventing
diabetes.
56 Improvements in beta cell function may contribute to the
beneﬁcial effects of L4-F on glucose homeostasis. Apolipoprotein/
ABCA1 interactions can also behave like a ligand/receptor system.
HDL-c initiates a calcium-sensitive signaling cascade through ABCA1
that stimulates CaMKK, which phosphorylates and activates
AMPK.
57,58 Thus, HDL-c has been shown to increase muscular glucose
uptake in patients with type 2 diabetes mellitus by activating AMP-
activated protein kinase in skeletal muscle in an ABCA1-dependent
manner. The current studies conﬁrm L-4F-induced phosphorylation of
not only AMPK but also AKT in the kidney, suggesting L-4F can
directly modulate insulin signaling and thereby improve glucose
regulation. Finally, reductions in inﬂammatory cytokines and increases
in adiponectin may also have a role in modulating insulin sensitivity
and restoring glucose tolerance.
29,59,60
In conclusion, we have demonstrated that targeting the apoA-I
fraction of HDL-c with a mimetic not only reduces cardiovascular
risk factors, but improves insulin sensitivity and vascular health in
both male and female obese mice. L-4F increases pAKT and
pAMPK in a manner dependent on HO activity. Furthermore,
our results demonstrate that the positive effects of L-4F are
independent of changes in body weight in ob female mice.
We believe that the increase in visceral fat observed in female ob
mice treated with L-4F is protective and may prevent the ectopic
accumulation of lipids in other insulin-sensitive tissues, a
hypothesis currently under investigation. Indeed, despite in-
creased visceral fat, L-4F increased insulin sensitivity, reduced
inﬂammatory cytokine levels and increased adiponectin levels.
In addition, overexpression of adiponectin in obese mice
promotes adipose tissue expansion, improved insulin and glucose
tolerance and reduced hepatic lipid accumulation.
33 If extrapo-
lated to humans, these results suggest that L-4F offers a powerful
pharmacological method of treating the metabolic syndrome that
may compliment weight loss therapy. L-4F appears to be a
promising therapeutic strategy for treating both cardiovascular
disease and insulin resistance in obese patients of either gender.
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